Form 4: Director Receives Shares in Lieu of Cash Compensation

Kleanthis Xanthopoulos, a Director at Connect Biopharma Holdings Ltd, received 3,738 ordinary shares as compensation for his services.

Summary

• Kleanthis Xanthopoulos, a Director of Connect Biopharma Holdings Ltd, received 3,738 ordinary shares on June 30, 2026.
• These shares were issued in lieu of a portion of his cash compensation for his 2026 annual board retainers, as per the company's Non-Employee Director Compensation Program.
• The shares were fully vested upon receipt.
• The number of shares was determined by dividing the equity value of the compensation by the average closing price of the company's ordinary shares over the 30 days preceding June 30, 2026, rounded down.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation transaction rather than a significant financial event for the company.

Positives

• Director compensation is being aligned with equity ownership, potentially aligning director interests with shareholders.
• The company has a structured compensation program for non-employee directors.
• The transaction was executed on June 30, 2026, indicating timely reporting.

Negatives

• The filing does not provide specific financial details regarding the value of the shares or the cash compensation foregone.

Risks

• The value of the shares received is subject to market fluctuations, which could impact the actual compensation received by the director.
• The calculation method for share issuance (rounding down) might result in a slight undervaluation of the compensation for the director.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a director's compensation transaction.

Industry Context

StockSavvy.ai notes that the issuance of equity in lieu of cash compensation to directors is a common practice in the biopharmaceutical industry, particularly for growth-stage companies seeking to conserve cash while incentivizing leadership.

Corporate Governance

Related Party Transactions

• The transaction involves a director receiving compensation, which is a related party transaction disclosed via Form 4.

Stakeholder Impact

• Shareholders: Potential for increased alignment of director interests with shareholders due to equity compensation.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• Continued service by Kleanthis Xanthopoulos as a Director of Connect Biopharma Holdings Ltd.
• Potential future compensation adjustments for directors based on the company's compensation program.

Key Dates

Keywords

Form 4, SEC Filing, Connect Biopharma Holdings Ltd, CNTB, Director Compensation, Equity Award, Share Issuance, Beneficial Ownership, Kleanthis Xanthopoulos